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In this study, we synthesized 4 methimazole (2-mercapto-1-methylimidazole, MMI) derivatives. The
kinetics of inhibition on mushroom tyrosinase by methimazole and its derivatives were investigated.
The results indicated that tert-butyl 3-methyl-2-sulfanylidene-2,3-dihydro-1H-imidazole-1-carboxylate
(compound 3; 3), 2-mercaptoimidazole (MI; compound 1; 1) and MMI (compound 2; 2) signiﬁcantly
inhibited tyrosinase activity in a dose-dependent manner, exhibiting an IC50 value of 1.50 mM,
4.11 mM, and 1.43 mM. However, compound 4 (4), compound 5 (5), and compound 6 (6) exerted no
inhibitory effect on mushroom tyrosinase activity. Kinetic analysis indicated that 3was a noncompetitive
tyrosinase inhibitor, whereas both 1 and 2 were exhibited as mixed-type tyrosinase inhibitors. Further-
more, 3 exerted a potent inhibitory effect on intracellular melanin formation in the B16/F10 murine mel-
anoma cells and did not cause cytotoxicity, as 1 and 2 did.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Introduction inhibitors that react with dopaquinone to form colorless products
8,9Melanin is synthesized by melanocytes distributed in the inner-
most layer of the epidermis.1 It plays a crucial role in protecting the
skin from the harmful effects of ultraviolet (UV) irradiation from
the sun.2 Although melanin can serve as a photoprotector, exces-
sive accumulation of melanin can cause hyperpigmentation in
food, which reduces food quality, and in skin, which induces age
spots and melasma spots.3,4 It has been reported that effective
tyrosinase inhibitors could potentially improve food quality and
cancer remedies, and ameliorate skin hyperpigmentation.5
Tyrosinase (EC1.14.18.1) is a copper-containing enzyme that
catalyzes two distinct reactions of melanin synthesis: the hydrox-
ylation of tyrosine by monophenolase action and the oxidation of
3,4-dihydroxyphenylalanine (L-DOPA) to o-dopaquinone.6 Tyrosi-
nase consists of two copper ions bound to six histidines at the
active site. Three types of tyrosinase (met-, oxy-, and deoxytyrosin-
ase) exhibiting different binuclear copper structures of the active
site are involved in the formation of melanin pigments.7 Based
on the interaction between the inhibitor and the enzyme, tyrosi-
nase inhibitors can be classiﬁed into four types, namely competi-
tive, uncompetitive, noncompetitive, and mixed.8
According to a previous study, thio-containing compounds act as
o-dopaquinone scavengers, which are well-known melanogenesisand reduce melanin production. In our previous study, a natural
amino acid ergothioneine, which contains a methimazole 2-mer-
capto-1-methylimidazole (MMI)-like structure, exerts a potent
inhibitory effect on tyrosinase activity.10 In this study, we conducted
experiments to synthesize methimazole derivatives, including a
methimazole amino acid, to evaluate their tyrosinase inhibitory ef-
fects. Methimazole is a thiourea derivative and is used as oral anti-
thyroid medication.11 In previous studies, the topical application of
5% MMI on the skin of brown guinea pigs for 6 weeks caused a sig-
niﬁcant reduction in the amount of epidermal melanin, resulting in
visually recognizable cutaneous depigmentation.12 In murine mela-
noma cells B16/F10, MMI acted as a potent melanin production
inhibitor.13 The results indicated that MMI can serve as a suitable
lead compound for developing novel tyrosinase inhibitors.
This study investigated the inhibitory effects of 2-mercaptoim-
idazole (MI; compound 1; 1), MMI (compound 2; 2), and four other
synthetic MMI derivatives (Fig. 1) on tyrosinase activity and intra-
cellular melanin formation in B16/F10 murine melanoma cells. We
also executed kinetic analysis to evaluate the enzyme kinetic
parameters and inhibition types.
2. Materials and methods
2.1. Chemicals
Mushroom tyrosinase, L-3,4-dihydroxyphenylalanine (L-DOPA),
kojic acid, 2-mercapto-1-methylimidazole, potassium carbonate,
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Figure 1. The structures and synthetic pathway of methimazole derivatives.
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hexane, MI, MMI, methyl 3-bromo-2-[(tert-butoxycarbonyl)-
amino]propanoate, dichloromethane, tetrahydrofuran, lithium
hydroxide monohydrate, dimethyl sulfoxide (DMSO), 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), al-
pha-Melanocyte-stimulating hormone (a-MSH), hydrogen perox-
ide, and magnesium sulfate were purchased from Sigma–Aldrich
(St. Louis, MO, USA). Dulbecco’s modiﬁed Eagle’s medium (DMEM),
fetal bovine serum (FBS), phosphate buffer solution (PBS), penicil-
lin G, streptomycin, and amphotericin were purchased from Gibco
Life Technologies Inc. (Carlsbad, CA, USA). Potassium dihydrogen
phosphate and dipotassium hydrogen phosphate were purchased
from Showa (Chemi Co. Ltd, Japan). B16/F10 mouse melanoma cell
lines were purchased from the Bioresource Collection and Research
Center (Hsinchu, Taiwan).
2.2. Synthetic methimazole derivatives
Figure 1 shows the structures and synthetic pathways of meth-
imazole derivatives. Brieﬂy, compound 3 (3) was prepared through
the reaction of an MMI (compound 2; 2) (400 mg, 3.5 mmol) and
potassium carbonate (968 mg, 7 mmol) in 7 mL of N,N-dimethyl-
formamide and the subsequently di-tert-butyl dicarbonate
(1.1 mL, 5.2 mmol) was added. The reaction mixture was stirred
at 60 C for 30 min in an N2 atmosphere. The resulting mixture
was partitioned between ethyl acetate (40 mL) and H2O (20 mL).
The organic layer was washed with brine (20 mL), dried over
MgSO4, and then concentrated in vacuo. The residue was separated
by chromatography over silica gel and eluted with hexane/ethyl
acetate (1:1) to afford 665 mg (89% yield) of 3 (Fig. 1).
Compound 4 (4) was prepared through the reaction of a mixture
of 2 (1.12 g, 9.8 mmol) and methyl 3-bromo-2-[(tert-butoxycar-
bonyl)-amino]propanoate (2.79 g, 9.8 mmol) in 35 mL of N,N-
dimethylformamide and the subsequently potassium carbonate
(2.71 g, 19.6 mmol) was added. The reaction mixture was stirred
at 70 C for 1 h in an N2 atmosphere. The resulting mixture was ﬁl-
tered and concentrated in vacuo. The residue was separated with
chromatography over silica gel and eluted with hexane/ethyl ace-
tate (3:7) to afford 2.60 g (87% yield) of 4.
Compound 5 (5) was prepared through the reaction of a mixture
of a solution of 4 (1 g, 3.2 mmol) in 16 mL of dichloromethane and
subsequently purged with hydrogen chloride gas for 30 min. The
mixture was partitioned in ether to afford 685 mg (86% yield) of
5 as a yellow solid.
Compound 6 (6) was prepared through the reaction of 5
(616 mg, 2.4 mmol) in 9.6 mL of tetrahydrofuran and subsequently
lithium hydroxide monohydrate (302 mg, 7.2 mmol) and H2O wereadded. The mixture was stirred at room temperature for 1.5 h and
the pH value was then adjusted to 4–5 with 1 N HCl(aq). The result-
ing mixture was concentrated in vacuo and puriﬁed by preparative
high-performance liquid chromatography (HPLC) with a gradient
MeOH/H2O system to afford 192 mg (39% yield) of 6.
The products were puriﬁed through recrystallization from eth-
anol and were identiﬁed using nuclear magnetic resonance
(NMR) and electrospray ionization mass spectrometry (ESI-MS)
analyses. The NMR data were acquired on a Mercury 400 MHz
NMR spectrometer from Varian (Agilent Technologies, Inc.).
2.3. Inhibitory effect of methimazole derivative on mushroom
tyrosinase
The reaction media, containing 20 lL of 0.1, 1, 2.5, and 10 mM
MMI and its derivatives, were mixed with 160 lL of 1 mM L-tyro-
sine and 20 lL of 212.64 lg/mL mushroom tyrosinase and dis-
solved in 5 mM dipotassium hydrogen phosphate in a 96-well
plate. A dipotassium hydrogen phosphate buffer served as a vehicle
control. All experiments were repeated in triplicate. The mixture
was incubated at 25 C for 30 min before measuring absorbance
at 475 nm, using an ELISA reader (Tecan, Austria). The tyrosinase
inhibition rate (%) was calculated as (1  ABSsample/ABScontrol) -
⁄ 100%. The IC50 value was determined through regression of a con-
structing dose–response curve at which 50% target activity was
lost.
2.4. Determining inhibition type and inhibition constant
In a 96-well plate, 20 lL of 0.1 (or 0.5), 1, 2, and 5 mMMMI and
its derivatives, were mixed with 160 lL of L-tyrosine (0.25, 0.5, 1, 2,
and 4 mM). Subsequently, 20 lL of varying concentrations of
mushroom tyrosinase were added and the formation of dopa-
chrome in the solution was monitored for 10 min by measuring
absorbance at 475 nm. The reaction was executed at a constant
temperature of 25 C. All experiments were conducted in triplicate.
The inhibition mechanism was assessed using Lineweaver–Burk
plots, and the inhibition constants were obtained from the second
plots of the apparent 1/Vmax and apparent Km/Vmax against the
inhibitor concentration, as described in Liao et al.10
2.5. Cell viability assay
B16/F10 cells were cultured in DMEM, supplemented with 10%
fetal bovine serum, 100 units/mL of penicillin G, 100 lg/mL of
streptomycin, and 0.25 lg/mL of amphotericin, and then incubated
at 37 C with 5% CO2. The viability of cells treated with 1 mM and
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thiazol tetrazolium (MTT) assay. Brieﬂy, 3  104 B16/F10 cells were
seeded and adhered in 96-well plates. After 24 h, DMEM was re-
moved and 200 lL of various concentrations of fresh DMEM and
methimazole derivative solution were added. The cells were then
incubated for 24 h. After incubation, the medium was removed,
and 100 lL of MTT in a PBS solution (0.5 mg/mL) was added to
each well. The cells were then incubated for 40 min at 37 C. Sub-
sequently, the MTT solution was removed, 100 lL of DMSO was
added to each well, and the plate was gently shaken to dissolve
the formazan crystals. The absorbance of each well was measured
at 570 nm by using the ELISA reader. All determinations were per-
formed in triplicate.
2.6. Assessment of melanin content
The cellular melanin content was determined as described
previously.14,15 Brieﬂy, 1  105 B16/F10 cells were seeded in
24-well plates and cultured at 37 C with 5% CO2 for 48 h. Subse-
quently, the cells were treated with 100 nM a-MSH for 24 h and
then with 1 mM methimazole derivatives or kojic acid for 24 h.
The cells werewashed twicewith PBS, and the cell pelletswere then
dissolved in 200 lL of 1 N NaOH in 10% DMSO for 1 h at 80 C.
The relative melanin content was determined by measuring
absorbance at 405 nm by using the ELISA reader (Tecan, Austria).
The melanin content was calculated using the following equation:
(Dsample/Dcontrol)  100%. All determinations were performed in
triplicate.2.7. Statistical analysis
All tests were conducted in triplicate. Statistical evaluation was
performed using Duncan’s multiple range tests and an analysis of
variance (ANOVA) by using SigmaStatR (Version 3.11.0, Systat
Software Inc., San Jose, CA, USA). The signiﬁcance level of the
analysis was a = 0.05, and a difference was considered statistically
signiﬁcant at a P value below 0.05 (⁄P <0.05).3. Results and discussion
3.1. Spectral data of the compounds
3.1.1. tert-Butyl 3-methyl-2-sulfanylidene-2,3-dihydro-1H-
imidazole-1-carboxylate (3)
Mp 86–87 C; 1H NMR (CDCl3, 400 MHz) d 1.59 (s, 9H), 3.54 (s,
3H), 6.58 (d, J = 2.8 Hz, 1H), 7.11 (d, J = 2.8 Hz, 1H); 13C NMR (CDCl3,
100 MHz) d 27.7, 34.8, 85.5, 114.4, 118.3, 147.0, 164.8; HRMS m/z
calcd for C9H14N2O2S: 214.0776. Found 214.0784.
[Explanation. 1H NMR spectrum: 1.59 ppm is corresponding to
the signal of the tert-butyl groups; 3.54 ppm is signal for methyl
group on the nitrogen; 6.58 ppm and 7.11 ppm are signals for dou-
ble bonds in the imidazole ring. 13C NMR spectrum: 34.8 ppm and
27.7 ppm are corresponding to the signals of the tert-butyl groups;
85.5 ppm is signal for methyl group on the nitrogen, 114.4 ppm
and 118.3ppm are signals for the double bounds (C@C) in the imid-
azole ring; 147.0 ppm is signal for thiourea (C@S); 164.8 ppm is
signals for carbamate group (C@O). HRMSm/z calcd for C9H14N2O2-
S: 214.0776. Found 214.0784. The experimental result is only
0.0008 difference to the theoretical value. All analytical data are
in accord with the compound 3.
3.1.2. Methyl 2-[(tert-butoxycarbonyl)amino]-3-(3-methyl-2-
sulfanylidene-2,3-dihydro-1H-imidazol-1-yl)propanoate (4)
Mp 106–107 C; 1H NMR (CDCl3, 400 MHz) d 1.23 (s, 9H), 3.58
(s, 3H), 3.76 (s, 3H), 4.49 (d, J = 6.4 Hz, 2H), 4.62 (q, J = 6.4 Hz,1H), 5.72 (d, J = 6.4 Hz, 1H), 6.64 (d, J = 2.4 Hz, 1H), 6.66 (d,
J = 2.4 Hz, 1H); 13C NMR (CDCl3, 100 MHz) d 28.2, 35.1, 47.9, 52.7,
53.5, 80.2, 117.5, 117.8, 155.2, 163.4, 170.3; HRMS m/z calcd for
C13H21N3O4S: 315.1253. Found 315.1248.
3.1.3. Methyl 2-amino-3-(3-methyl-2-sulfanylidene-2,3-
dihydro-1H-imidazol-1-yl) propanoate hydrochloride (5)
Mp 177–178 C; 1H NMR (D2O, 400 MHz) d 3.40 (s, 3H), 3.70 (s,
3H), 4.43 (dd, J = 16.4, 8.0 Hz, 1H), 4.55–4.61 (m, 2H), 6.88 (d,
J = 4.0 Hz, 1H), 6.91 (d, J = 4.0 Hz, 1H). 13C NMR (CD3OD,
100 MHz) d 35.5, 47.6, 53.3, 54.2, 119.0, 120.6, 164.2, 168.5.; HRMS
m/z calcd for C8H13N3O2S (1M HCl): 215.0728. Found 215.0726.
3.1.4. 2-Amino-3-(3-methyl-2-sulfanylidene-2,3-dihydro-1H-
imidazol-1-yl)propanoic acid (6)
Mp 224–225 C; 1H NMR (D2O, 400 MHz) d 3.38 (s, 3H), 4.04
(dd, J = 6.4, 4.0 Hz, 1H), 4.27 (dd, J = 15.2, 6.4 Hz, 1H), 4.54 (dd,
J = 15.2, 4.0 Hz, 1H), 6.82 (d, J = 2.4 Hz, 1H), 6.85 (d, J = 2.4 Hz,
1H). 13C NMR (D2O, 100 MHz) d 35.2, 47.5, 55.1, 118.8, 120.4,
159.3, 171.2.; HRMS m/z calcd for C7H11N3O2S: 201.0572. Found
201.0579.
3.2. Inhibitory effect of a methimazole derivative on mushroom
tyrosinase
Tyrosinase functions both as a monophenolase and an o-diphe-
nolase. We investigated the effects of a methimazole derivative on
the monophenolase activity of mushroom tyrosinase on substrate
tyrosine. No inhibition of 4, 5, or 6 was detected on mushroom
tyrosinase activity. Figure 2A and B shows the time courses of oxi-
dation in the presence of various concentrations of 1, 2, and 3.
Curves 1–5 represent inhibitor concentrations of 0, 0.1, 1, 2, 5,
and 10 mM, respectively. When the system reached a steady state
as the characteristic of monophenolase activity was observed
(Fig. 2A), the lag time was detected (Fig. 2B).16 The lag time in-
creased in a dose-dependent manner as the concentrations of 1,
2, and 3 increased. The concentrations of 1, 2, and 3 caused a
50% loss in enzyme activity (IC50) and were determined to be
4.13 mM, 1.43 mM, and 1.50 mM, respectively (Table 1). The
mechanism for the monophenolase activity of tyrosinase has been
widely studied because monophenol can react only with the oxy
form and oxidized to the o-quinone, resulting in a deoxy form
ready for further dioxygen binding.6 Thus, monophenolase activity
presents a characteristic lag time that increases depending on the
concentrations of the enzyme inhibitor.17 The time can be short-
ened using reducing agents, such as (+)-catechin.18
3.3. The inhibition type and inhibition constant of compound 1
and compound 2 on mushroom tyrosinase activity
The inhibition kinetics of 1 and 2 on the enzyme was studied
using Lineweaver–Burk plots. As shown in Figures 3A and 4A, the
results of the Lineweaver–Burk double-reciprocal plots yielded a
group of lines that intercepted at the second quadrant. This result
indicated that 1 and 2 were mixed-type monophenolase inhibitors
of mushroom tyrosinase. In previous studies, 2 has been reported
as a mixed-type inhibitor of diphenolase by using L-DOPA as a sub-
strate.19 However, this is the ﬁrst time that 1 and 2 have exhibited
potent monophenolase activity. The result indicated that 1 and 2
can bind with a free enzyme as well as with an enzyme-substrate
complex. Regarding 1 and 2, their equilibrium constant KI was
much less than KIS (Figs. 3B, C, 4B, and C), indicating that the afﬁn-
ity of the inhibitor for a free enzyme was stronger than that for an
enzyme–substrate complex.20 The inhibitor constants obtained are
listed in Table 1 for comparison.
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Figure 2. Effects of the 1, 2 and 3 on monophenolase activity of mushroom tyrosinase. (A) The progress curves for the oxidation of L-tyrosine by the enzyme. The inhibitor
concentrations for Curves 0–5 were 0, 0.1, 1, 2, 5, and 10 mM, respectively. (B) The effects of 1, 2, and 3 on the lag time of mushroom tyrosinase.
Table 1
The IC50 and inhibition constants of 1, 2 and 3 on mushroom tyrosinase
1 2 3
IC50 (mM) 4.11 ± 0.29 1.43 ± 0.06* 1.45 ± 0.14*
KI (mM) 0.57 0.47 1.75
KIS (mM) 2.80 1.91 1.75
Inhibition type Mixed Mixed Noncompetitive
Each column represents the mean ± SD of 3 independent experiments.
* P <0.05, compare with the 1.
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on mushroom tyrosinase activity
The kinetic behavior of the oxidation of L-tyrosine by mushroom
tyrosinase at various concentrations of 3 is shown in Figure 5. The
Lineweaver–Burk double-reciprocal plots indicated that 3 was a
noncompetitive inhibitor that decreased the apparent value of
Vmax, exerting no effect on that of Km (Fig. 5A). The result alsoindicated that 3 can bind to a free enzyme as well as to an en-
zyme-substrate complex.
We obtained the equilibrium constant for inhibitor binding by
using the free enzyme, KI, and the enzyme-substrate complex,
KIS, from the second plots of the apparent Km/Vmax (Kmapp/Vmaxapp)
and 1/Vmax (1/Vmaxapp) versus the inhibitor concentrations (Figs. 5B
and C). The inhibitor constants are listed in Table 1 for comparison.
3.5. Cell viability and assessment of melanin content
Numerous tyrosinase inhibitors have been reported to exert no
inhibitory effects on melanin content in melanoma cells. Thus, 1, 2,
and 3 were further subjected to melanin content and cell viability
assays to evaluate their inhibitory effect on melanogenesis. As
shown in Figure 6A, the 1-mM or 2-mM 3 did not induce any
cytotoxicity in the B16/F10 cells, whereas 1 and 2 induced signiﬁ-
cant cytotoxicity at concentrations of 1 mM and 2 mM, respec-
tively. The inhibitory effects of 1, 2, and 3 on a-MSH-mediated
melanogenesis were determined by measuring the quantity of
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Figure 6B. The 1-mM 2 and 3 substantially reduced the a-MSH-
induced cellular melanin contents, compared with the grouptreated with a-MSH alone, and was as effective as kojic acid
(positive control) (Fig. 6B). The inhibitory effects of 1-mM 2, 3,
and kojic acid on melanin production were 88.7%, 49.3%, and
[Inhibitor]
K m
ap
p/
V m
ax
ap
p
0
40
80
120
160
[Inhibitor]
0 1 2 3 4 5 6
0 1 2 3 4 5 6
1/
V m
ax
ap
p
0
40
80
120
(A)
1/[S] (mM)-1
-2 0 2 4 6
1/
V(
O
.D
. 4
75
/m
in
)-1
-200
0
200
400
600
800
1000
(C)
(B)
1
3
2
4
Figure 5. Determination of the inhibitory type and inhibition constants of 3. (A) The Lineweaver–Burk plots for the inhibition of 3 on mushroom tyrosinase. The inhibitor
concentrations for Curves 1–4 were 0, 1, 2, and 5 mM. (B) KI was obtained from the second plot of the apparent Km/Vmax. (C) KIS was obtained from the second plot of the
apparent 1/Vmax.
2814 C.-F. Chan et al. / Bioorg. Med. Chem. 22 (2014) 2809–281556.9%, respectively. The results of this study suggested that 3 can
inhibit mushroom tyrosinase activity and also exhibit potent mela-
nogenesis inhibition on B16/F10 cells.
4. Discussion
In previous studies, the tyrosinase structure consisted of two
copper ions in the active center of tyrosinase, and a lipophilic
long-narrow gorge near the active center has been observed.21 A
previous study determined that for an optimal inhibition of tyros-
inase, electronegative substitution is essential because the active
site of the enzyme might contain hydrophobic sites, and the posi-
tion is also critical for the inhibition because of the conformational
space.22 Compounds 1–6 contain sulfur atoms that might all be
able to chelate with the dicopper nucleus in the active site and
inactivate the tyrosinase catalyzing ability.23 However, 4, 5, and
6 exhibited weak tyrosinase inhibition activity, which might have
been due to stereo-hindrance or a negative position of imidazole
ring substitution. This would cause these compounds to occur near
the active center of tyrosinase difﬁculties. Even if these compounds
could enter the active center to form the chelation with the binu-
clear copper, the weak interactions of hydrophilic 4, 5, and 6 with
the hydrophobic protein pocket of the enzymes would render the
chelation unstable.24 Another reason for the unstable chelation
might have been that 4, 5, and 6 were separated by an additional
one ethyl group, compared with 3. The change in the inhibitory
activity of the obtained 4, 5, and 6 was not signiﬁcant.
Previous reports have indicated that 2 can chelate copper at the
active site of an enzyme and also conjugate with o-dopaquinone to
decrease the extent of pigmented product formation.19 The inhib-
itory activity of 1 on tyrosinase was signiﬁcantly less effective,
compared with 2 (Table 1). The result might have been due to
the higher hydrophilicity of 1 that retards the compound near
the active center of tyrosine, compared with 2. The 3 is a relatively
nonpolar molecule, compared with 1, and can occur near thetyrosinase active center to form a reversible noncovalent complex
with the tyrosinase.23 Thus, mixed tyrosinase with 2 and 3 might
form a tight conjugation complex by its sulfur and nitrogen atom
through a hydrogen and coordinate bond. This tight complex could
cause the free oxygen molecule to decrease its reaction ability and
even render it unable to participate in hydroxylation with mon-
ophenols and in oxidation with o-diphenols. Thus, the tyrosinase
would lose its catalyzing ability with monophenols.25
In previous studies, 2 has been determined to function both as a
monophenolase and diphenolase inhibitor.19 In addition, the inhi-
bition type of 2 on diphenolase was observed to be mixed.19 How-
ever, no reports on the inhibition type of 1 and 2 on
monophenolase are available. This study is the ﬁrst to report that
both 1 and 2 belong to the mixed-type monophenolase inhibitors.
3 is a noncompetitive inhibitor, suggesting that the inhibition
mechanism of 3 differs from that of 2.
According to the result, 2 and 3 exhibited more potent inhibi-
tory effects on intracellular melanin formation than 1 in B16/F10
melanoma cells. The viability assay of 1, 2, and 3 on the B16/F10
melanoma cells indicated that the descending order of cytotoxicity
was 1 > 2 > 3. Even the 2-mM 3 did not exert cytotoxic effects on
the B16/F10 melanoma cells. It is unclear whether 3 can competi-
tively bind to melanocortin 1 receptor (MCR-1) and thereby re-
press alpha-melanocyte stimulating hormone (a-MSH)-induced
melanogenesis or whether directly inhibiting intracellular tyrosi-
nase activity inhibits intracellular melanin formation. This study
suggests that the elucidation of the inhibition mechanism of 3 on
tyrosinase and melanogenesis is crucial and must be further inves-
tigated in the future.
5. Conclusion
The hydrophobic derivatives of methimazole, such as 4, 5, and
6, exerted no inhibitory effect on monophenolase activity, which
might have been due to difﬁcultly in interacting with the
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Figure 6. Effects of 1, 2 and 3 on cell viability and melanin content of B16F10. (A)
The effects of 1, 2, and 3 on cell viability of the B16/F10 cells. The B16/F10 cells were
treated with various concentrations of 1, 2, and 3 for 24 h. Cell viability was
determined using an MTT assay. Each percentage value of the treated cells was
calculated and compared with that of the control cells. (B) The effects of 1, 2, and 3
and kojic acid on the cellular melanin content in the B16/F10 melanoma cells. The
control readings were set at 100%. Data from experimental wells are expressed as
percentages of the controls. Each column represents the mean ± SD of three
independent experiments. ⁄P <0.05, compared with the a-MSH alone.
C.-F. Chan et al. / Bioorg. Med. Chem. 22 (2014) 2809–2815 2815hydrophobic active center. 1 is an ineffective mixed-type mono-
phenolase inhibitor and exerts potent cytotoxicity on the B16/
F10 melanoma cells. 2 is a potent mixed-type monophenolase
inhibitor but also exhibits cytotoxicity at a 2-mM concentration.3 is a potent noncompetitive monophenolase inhibitor and exhib-
its no cytotoxicity. The study determined that 3 might exert bene-
ﬁcial effects in the clinical treatment of skin depigmentation in the
future.
Acknowledgment
The authors thank the National Science Council, Taiwan, ROC
for the ﬁnancial support (NSC102-2622-E-241-006-CC3).Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.bmc.2014.03.009.
These data include MOL ﬁles and InChiKeys of the most important
compounds described in this article.
References and notes
1. Spritz, R. A.; Hearing, V. J., Jr Genetic Disorders of Pigmentation. In Advanced
Human Genetics; Harris, H., Hirschhorn, K., Eds.; Springer: US, 1994; p 1.
2. Gilchrest, B. A.; Eller, M. S. J. Invest. Dermatol. 1999, 4, 35.
3. Friedman, M. J. Agric. Food Chem. 1996, 44, 631.
4. Matsuura, R.; Ukeda, H.; Sawamura, M. J. Agric Food Chem. 2006, 54, 2309.
5. Seo, S.-Y.; Sharma, V. K.; Sharma, N. J. Agric. Food Chem. 2003, 51, 2837.
6. Kim, Y. J.; Uyama, H. Cell. Mol. Life Sci. 2005, 62, 1707.
7. Fenoll, L. G.; Rodrıìguez-López, J. N.; Garcı´a-Sevilla, F.; Garcı´a-Ruiz, P. A.; Varón,
R.; Garcı´a-Cánovas, F.; Tudela, J. BBA-Protein Struct. Mol. 2001, 1548, 1.
8. Chang, T.-S. Int. J. Mol. Sci. 2009, 10, 2440.
9. Tsuji-Naito, K.; Hatani, T.; Okada, T.; Tehara, T. Bioorg. Med. Chem. 2007, 15,
1967.
10. Liao, W.; Wu, W.; Tsai, P.-C.; Wang, H.-F.; Liu, Y.-H.; Chan, C.-F. Appl. Biochem.
Biotechnol. 2012, 166, 259.
11. Rossi, A. M.; Perez, M. I. Facial Plast. Surg. Clin. North Am. 2011, 19, 313.
12. Kasraee, B. J. Invest. Dermatol. 2002, 118, 205.
13. Kasraee, B.; Hügin, A.; Tran, C.; Sorg, O.; Saurat, J.-H. J. Invest. Dermatol. 2004,
122, 1338.
14. Jang, J. Y.; Kim, H. N.; Kim, Y. R.; Choi, Y. H.; Kim, B. W.; Shin, H. K.; Choi, B. T. J.
Ethnopharmacol. 2012, 141, 338.
15. Palumbo, A.; d’Ischia, M.; Misuraca, G.; Prota, G. Biochim. Biophys. Acta 1991,
1073, 85.
16. Yang, M.-H.; Chen, C.-M.; Hu, Y.-H.; Zheng, C.-Y.; Li, Z.-C.; Ni, L.-L.; Sun, L.;
Chen, Q.-X. J. Biosci. Bioeng. 2013, 115, 514.
17. Wang, Q.; Shi, Y.; Song, K.-K.; Guo, H.-Y.; Qiu, L.; Chen, Q.-X. Protein J. 2004, 23,
303.
18. Kim, Y.-J.; Chung, J. E.; Kurisawa, M.; Uyama, H.; Kobayashi, S.
Biomacromolecules 2004, 5, 474.
19. Andrawis, A.; Kahn, V. Biochem. J. 1986, 235, 91.
20. Bar, M. Master Thesis, Magister Science, University of the Free State, 2001.
21. Shimizu, K.; Kondo, R.; Sakai, K. Planta Med. 2000, 66, 11.
22. Khan, M. T. H.; Choudhary, M. I.; Khan, K. M.; Rani, M.; Attaur, R. Bioorg. Med.
Chem. 2005, 13, 3385.
23. Liu, J.; Wu, F.; Chen, L.; Hu, J.; Zhao, L.; Chen, C.; Peng, L. Bioorg. Med. Chem. Lett.
2011, 21, 2376.
24. Yi, W.; Cao, R. H.; Chen, Z. Y.; Yu, L.; Ma, L.; Song, H. C. Chem. Pharm. Bull. 2009,
57, 1273.
25. Liu, J.; Yi, W.; Wan, Y.; Ma, L.; Song, H. Bioorg. Med. Chem. 2008, 16, 1096.
